U.S., March 13 -- ClinicalTrials.gov registry received information related to the study (NCT07468526) titled 'An Ultra-short Course of Primaquine for the Radical Cure of Vivax Malaria' on Jan. 13.
Brief Summary: Current treatment regimens to prevent relapsing malaria are too long. A shorter higher dose treatment could improve treatment outcomes, but this needs to be balanced against increased risk of side effects. Recent data from a trial in children in Papua New Guinea (PNG) suggests a shortened treatment of 3 days is safe and effective. Our multicentre trial will assess the safety and efficacy of an ultra-short primaquine course. This trial is expected to directly influence global treatment policies.
Study Start Date: June 01, 2026
Stu...